Cutaneous Adverse Events Associated with Immune Checkpoint Inhibitors: A Review Article

Immune checkpoint inhibitors (ICIs) have emerged as novel options that are effective in treating various cancers. They are monoclonal antibodies that target cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed cell death 1 (PD-1), and programmed cell death-ligand 1 (PD-L1). However, activation of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Chieh-Hsun, Yu, Hsin-Su, Yu, Sebastian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9032875/
https://www.ncbi.nlm.nih.gov/pubmed/35448208
http://dx.doi.org/10.3390/curroncol29040234

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9032875/
https://www.ncbi.nlm.nih.gov/pubmed/35448208
http://dx.doi.org/10.3390/curroncol29040234

Ejemplares similares